Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 28:14:13.
doi: 10.1186/s12916-016-0552-3.

Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study

Affiliations

Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study

Tilman Kühn et al. BMC Med. .

Abstract

Background: First metabolomics studies have indicated that metabolic fingerprints from accessible tissues might be useful to better understand the etiological links between metabolism and cancer. However, there is still a lack of prospective metabolomics studies on pre-diagnostic metabolic alterations and cancer risk.

Methods: Associations between pre-diagnostic levels of 120 circulating metabolites (acylcarnitines, amino acids, biogenic amines, phosphatidylcholines, sphingolipids, and hexoses) and the risks of breast, prostate, and colorectal cancer were evaluated by Cox regression analyses using data of a prospective case-cohort study including 835 incident cancer cases.

Results: The median follow-up duration was 8.3 years among non-cases and 6.5 years among incident cases of cancer. Higher levels of lysophosphatidylcholines (lysoPCs), and especially lysoPC a C18:0, were consistently related to lower risks of breast, prostate, and colorectal cancer, independent of background factors. In contrast, higher levels of phosphatidylcholine PC ae C30:0 were associated with increased cancer risk. There was no heterogeneity in the observed associations by lag time between blood draw and cancer diagnosis.

Conclusion: Changes in blood lipid composition precede the diagnosis of common malignancies by several years. Considering the consistency of the present results across three cancer types the observed alterations point to a global metabolic shift in phosphatidylcholine metabolism that may drive tumorigenesis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Plasma metabolite concentrations and cancer risk. P values from Cox regression analyses on individual metabolite concentrations on the log-2 scale and cancer risk are represented by the needles. The blue dashed lines depict the significance threshold at an uncorrected P <0.05 and green dashed lines depict the significance threshold after Bonferroni correction (0.05 divided by 120). Unfilled circles indicate inverse associations and filled circles indicate direct associations. Metabolites are grouped by chemical properties: block 1, acylcarnitines; block 2, amino acids; block 3, biogenic amines; block 4, lysophosphatidylcholines (lysoPCs); block 5, diacylphosphatidylcholines; block 6, acyl-alkyl-phosphatidylcholines; block 7, sphingolipids; and block 8, overall hexoses. All multivariable Cox regression models were adjusted for age, smoking (never, former, current), lifetime alcohol intake (g/d), current aspirin use (yes/no), physical activity (Cambridge index), waist circumference (cm), BMI (continuous), height (cm), and education level (primary school, secondary school, university degree). Analyses on breast cancer risk were additionally adjusted for menopausal status, current HRT use (yes/no), current oral contraceptive use (yes/no), and at least one full term pregnancy (yes/no). Analyses on colorectal cancer risk were additionally adjusted for sex, fiber intake (g/d), and processed meat intake (g/d)
Fig. 2
Fig. 2
Age- and sex-adjusted Spearman’s correlations between levels of different lysoPCs

Similar articles

Cited by

References

    1. Liesenfeld DB, Habermann N, Owen RW, Scalbert A, Ulrich CM. Review of mass spectrometry-based metabolomics in cancer research. Cancer Epidemiol Biomarkers Prev. 2013;22(12):2182–201. doi: 10.1158/1055-9965.EPI-13-0584. - DOI - PMC - PubMed
    1. Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. 2014;20(10):1193–8. doi:10.1038/nm.3686 - PMC - PubMed
    1. Mondul AM, Moore SC, Weinstein SJ, Karoly ED, Sampson JN, Albanes D. Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study. Int J Cancer. 2015;137(9):2124–32. doi: 10.1002/ijc.29576. - DOI - PMC - PubMed
    1. Cross AJ, Moore SC, Boca S, Huang WY, Xiong X, Stolzenberg-Solomon R, et al. A prospective study of serum metabolites and colorectal cancer risk. Cancer. 2014;120(19):3049–57. doi: 10.1002/cncr.28799. - DOI - PMC - PubMed
    1. Fages A, Duarte-Salles T, Stepien M, Ferrari P, Fedirko V, Pontoizeau C, et al. Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. BMC Med. 2015;13:242. doi: 10.1186/s12916-015-0462-9. - DOI - PMC - PubMed

Publication types